EDDING GENOR GROUP HOLDINGS LIMITED
亿腾嘉和醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board (the "**Board**") of directors (the "**Directors**") of Edding Genor Group Holdings Limited (the "Company", and together with its subsidiaries, the "**Group**") is pleased to announce the interim consolidated results of the Group for the six months ended 30 June 2026 (the "**Reporting Period**"), together with the comparative figures for the six months ended 30 June 2025. The interim consolidated financial statements of the Group for the Reporting Period have been reviewed by the audit committee of the Company (the "**Audit Committee**") and the Company's auditor.

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group.

KEY FINANCIAL HIGHLIGHTS

- Revenue for the Reporting Period was RMB872.7 million.
- Net loss was RMB65.9 million for the six months ended 30 June 2026.
- Cash and cash equivalents were RMB913.0 million as at 30 June 2026.
- Net cash flows from operating activities for the Reporting Period were RMB337.4 million.
- For the Reporting Period, adjusted EBITDA was RMB204.8 million.

* *Note:*

All numbers in this "Key Financial Highlights" section are subject to rounding adjustments and therefore approximate numbers only.

For the definition and reconciliation of the most directly comparable HKFRS measure and the adjusted EBITDA (non-HKFRS measure), please refer to "Financial Review – Management Discussion and Analysis – Non-HKFRS Measures" in this announcement.

BUSINESS REVIEW

First Half of 2026: Completion of the Merger, Focus on Innovation

The first half of 2026 marked the first full six-month operating period of the Group following completion of the strategic Merger and represented a critical turning point that built on past achievements while ushering in the future, underpinned by a firm commitment to innovation. We completed our post-Merger strategic refocusing, achieved multiple milestone advances across our product pipeline and accelerated the operation of our innovation engine. The Group's innovation positioning, pipeline progress and management execution all reached record-high levels. Our strategic vision and core capabilities are now highly aligned, our differentiated platform strategy has become increasingly clear, and the benefits of resource aggregation are poised to be fully unleashed.

Deepening Our Presence in Breast Cancer Treatment. In June 2026, the Group's investigational new drug application (the "**IND**") for a Phase Ib/II clinical trial of GB268, a highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody, for the treatment of locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, was approved by the National Medical Products Administration (the "**NMPA**"). The clinical trial will explore monotherapy, immunotherapy in combination with chemotherapy and immunotherapy in combination with antibody-drug conjugates, covering the full course of treatment from first-line to later-line settings. Leveraging the innovative trispecific antibody GB268 and a highly differentiated clinical strategy, together with the innovative CDK4/6 inhibitor Rujianing, which was launched and included in the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (the "**NRDL**") in 2025 and possesses both first-line and second-line indications for advanced HR+/HER2- breast cancer, the Group will continue to explore and deepen its presence in the breast cancer treatment field. The Group plans to present Phase I clinical data for GB268 monotherapy at the annual meeting of the European Society for Medical Oncology ("**ESMO**") in October 2026. Meanwhile, following the achievement of the primary endpoint in 2024 by GB491-008, the Phase III clinical trial of Rujianing as first-line treatment for advanced HR+/HER2- breast cancer, the study has continued in accordance with the protocol, and the relevant study data are expected to be presented at the San Antonio Breast Cancer Symposium ("**SABCS**") in December 2026. This marks the beginning of the Group's comprehensive and in-depth development in breast cancer treatment, one of the world's largest oncology drug markets.

Frontier Exploration in Large-Molecule Antibody Therapeutics. The Group has successfully established a comprehensive and highly efficient large-molecule antibody drug development platform integrating discovery, innovation and application. The Group is committed to continuous innovation across multiple molecular formats, including bispecific and multispecific antibodies, T-cell engagers, antibody-drug conjugates and nanobodies, with a view to addressing significant unmet clinical needs. In April 2026, the Group presented preclinical data for its internally developed, highly innovative tetraspecific T-cell engager EDP001 (CD3/CD19/CD19/BCMA) at the annual meeting of the American Association for Cancer Research ("**AACR**"). Preclinical studies demonstrated that EDP001 possesses potent in vitro cytotoxic activity, significant in vivo tumour growth inhibition and low levels of cytokine release, indicating promising clinical application prospects in B-cell lymphoma and B-cell-related autoimmune diseases and demonstrating the Group's determination to pursue frontier exploration in large-molecule antibody therapeutics.

Building Core Competitiveness in Chronic Disease. In February 2026, the Group formally initiated a Phase II clinical study of EDP167, an siRNA therapeutic targeting hepatic angiopoietin-like protein 3 (ANGPTL3), for homozygous familial hypercholesterolaemia ("**HoFH**"), and completed enrolment of the last subject in June. A Phase II clinical study for mixed dyslipidaemia is expected to be initiated in the fourth quarter of 2026. The Group plans to present the Phase I clinical data for EDP167 at the European Society of Cardiology ("**ESC**") Congress in August 2026. Leveraging its small nucleic acid drug R&D platform, which covers various classes of small nucleic acid therapeutics, including siRNA and antisense oligonucleotides ("**ASO**"), across chronic disease areas such as cardiovascular, metabolic, autoimmune and liver diseases, and in synergy with the Group's commercialised innovative product Vascepa, the first triglyceride-lowering therapy approved by both the FDA and the NMPA that can reduce the risk of cardiovascular events, the Group is continuously strengthening its core competitiveness in the chronic disease field and providing more high-quality treatment options for chronic disease management.

Initial Validation of the Global Value of Our Pipeline. The global collaboration in relation to GB261, the Group's CD3/CD20 bispecific T-cell engager, has been further deepened. On 17 June 2026, UCB S.A. ("**UCB**") completed its acquisition of Candid Therapeutics, Inc. ("**Candid**"), the licensee of the overseas rights to GB261. On 16 July 2026, the Group received proceeds of US$48,419,599.63 as partial consideration to which it was entitled for the disposal of its entire equity interest in Candid and is entitled, in accordance with the merger agreement, to a pro rata share of clinical development milestone payments of up to US$200 million and other potential future payments. Meanwhile, the Group remains entitled to receive milestone payments in connection with the subsequent development of GB261 and tiered royalties calculated based on future net sales. This transaction has initially validated the global collaboration value of the Group's pipeline.

BUSINESS OUTLOOK

Outlook: Creating Value through Innovation with Long-Term Strategic Resolve

Looking ahead, the Group will maintain its long-term strategic resolve, remain firmly committed to innovation, deepen its platform strategy, accelerate R&D and clinical progress and make every effort to realise value creation.

Focus on Key Data Readouts and Accelerate R&D and Clinical Progress. The second half of 2026 is expected to mark an initial harvest of data from the Company's product pipeline. GB268 is planned to present preliminary Phase I clinical data at the ESMO annual meeting in October 2026, the clinical trial data for Rujianing are expected to be presented at SABCS in December 2026, and the Phase I clinical data for EDP167 will be presented at the ESC Congress in August 2026. The Group will actively advance the clinical development of pipeline products including GB268, EDP167 and EDP001, and the development of multiple drug candidates currently in the discovery and preclinical stages. These programmes focus on addressing significant unmet clinical needs and aim to overcome the limitations and technical bottlenecks of existing therapies, thereby continuously building a highly differentiated and competitive R&D pipeline.

Leverage Differentiated Platform Synergies and Deepen Our Presence in High-Potential Sub-Markets. The Group will continue to advance its differentiated strategy, focusing on three core areas of oncology, autoimmune diseases and cardiometabolic diseases, and establishing differentiated competitive barriers in bispecific and multispecific antibodies, T-cell engagers, antibody-drug conjugates and small nucleic acid therapeutics. Meanwhile, the Group will deepen its platform strategy based on a long-term approach. In particular, in the two major markets of breast cancer treatment and cardiovascular chronic diseases, where the Group has established strategic positions in both R&D and commercialisation, the Group will leverage its highly differentiated synergistic advantages in R&D and commercialisation to establish and deepen its presence in sub-markets with significant market potential. The Group will also continue to optimise its product portfolio, concentrate its innovation resources and actively pursue global collaboration opportunities that best serve the Group's development.

We remain confident in the Group's long-term development prospects and will continue to apply pragmatic and efficient management to drive the growth of Edding Genor into a globally competitive leading biopharmaceutical enterprise.

BUSINESS HIGHLIGHTS

Our Product and Pipeline Portfolios

The Group has established two differentiated and competitive frontier technology platforms for large-molecule biologics and innovative small nucleic acid therapeutics and has built an integrated, full-chain innovative drug R&D system. Its business covers the entire lifecycle from early-stage drug target discovery, molecular structure design and optimisation, IND-enabling studies, clinical development and regulatory submission through to commercialisation, providing the Group with end-to-end, independently controlled R&D capabilities from original innovation to market translation. The Group's current pipeline comprises three clinical-stage innovative drugs and multiple preclinical products in development, focusing on major therapeutic areas including oncology, autoimmune diseases, chronic inflammation, cardiometabolic diseases and respiratory diseases. By focusing on unmet clinical needs and cultivating high-potential innovative fields, the Group aims to enhance its core competitiveness and industry influence in the innovative drug sector. The Group's commercialised product portfolio comprises originator-branded products and innovative products.

Pipeline In-development

	Project	Targets/Modality	Indications	Discovery	PCC	IND enabling	Phase I/II	Phase III
Cancer	GB268	PD-1/CTLA-4/VEGF	BC					
			CRC					
			NSCLC					
			BTC					
	GB261	CD3/CD20	B lymphoma, AID					
	EDP004	CD3/BCMA/GPRC5D	MM					
	GBD201	CCR8/CTLA-4	Solid Tumor					
	EDP015	BsAb-ADC	BC					
	EDP012	BsAb-ADC	LC					
Autoimmune/ Inflammation	EDP001	CD3/CD19/CD19/BCMA	Autoimmune diseases					
	EDP007	BsAb /multi-specific Ab	Asthma, COPD, AD					
Cardiometabolic/ Nephrology	EDP167	ANGPTL3	HoFH					
			Mixed Hyperlipidemia					
	EDP168	siRNA-bispecific	Hyperlipidemia, ASCVD					
	EDP169	siRNA	IgAN					
	EDP173	siRNA-bispecific	Hyperlipidemia, ASCVD					

- **Key progress made during the Reporting Period**

R&D Pipeline

- ***GB268 (a trispecific antibody targeting PD-1/CTLA-4/VEGF)***

  GB268 received clinical trial approval from the NMPA in July 2025. Preliminary data from the 10 mg/kg to 30 mg/kg dose cohorts of the Phase I monotherapy study demonstrated favourable safety and tolerability, encouraging PK/PD profiles and anti-tumour activity across all dose cohorts. In June 2026, GB268 received approval from the NMPA for a Phase Ib/II clinical trial for the treatment of locally advanced unresectable or metastatic breast cancer, including TNBC and HR+/HER2- breast cancer, to explore monotherapy, immunotherapy in combination with chemotherapy and immunotherapy in combination with antibody-drug conjugates. GB268 is subsequently expected to undergo Phase II clinical studies as monotherapy or in combination therapy in multiple solid tumours, including but not limited to advanced breast cancer, non-small cell lung cancer, colorectal cancer, biliary tract cancer and other solid tumours. The Phase I clinical data for GB268 monotherapy will be presented at the ESMO annual meeting in October 2026.

- ***EDP167 (a small interfering RNA[siRNA] therapeutic targeting hepatic angiopoietin-like protein 3 [ANGPTL3])***

  EDP167 received clinical trial approval from the NMPA in June 2025 and successfully completed a Phase I clinical study in healthy volunteers and subjects with mild dyslipidaemia in December 2025. The results demonstrated overall favourable safety and tolerability and the ability of EDP167 to comprehensively improve the atherogenic lipid profile, indicating that EDP167 has the potential to be among the best-in-class therapies targeting ANGPTL3 and supporting its further clinical evaluation. In February 2026, a Phase II clinical study of EDP167 for HoFH was formally initiated, and enrolment of the last subject was completed in June 2026. Primary endpoint analysis is expected to be completed in the fourth quarter of 2026. A Phase II clinical study of EDP167 for mixed dyslipidaemia is expected to be initiated in the fourth quarter of 2026. The Phase I clinical data for EDP167 will be presented at the ESC Congress in August 2026.

- ***GB261 (a bispecific T-cell engager targeting CD3/CD20)***

  On 17 June 2026, UCB completed its acquisition of Candid, the licensee of the overseas rights to GB261. On 16 July 2026, the Group received proceeds of US$48,419,599.63 as partial consideration to which it was entitled for the disposal of its entire equity interest in Candid and is entitled, in accordance with the merger agreement, to a pro rata share of clinical development milestone payments of up to US$200 million and other potential future payments. Meanwhile, the Group remains entitled to receive milestone payments in connection with the subsequent development of GB261, with aggregate milestone payments of up to US$443 million, and tiered royalties on future net sales at rates ranging from single-digit to double-digit percentages.

- ***EDP001 (a tetraspecific T-cell engager targeting CD3/CD19/CD19/BCMA)***

  EDP001 is primarily intended for the treatment of multiple B-cell-driven autoimmune diseases. The molecule features high-specificity and high-affinity binding to both BCMA and CD19, with a dual-epitope CD19 design that significantly enhances binding to CD19+ B cells and enables efficient B-cell depletion, while simultaneously targeting BCMA to eliminate autoantibody-secreting plasma cells. The CD3 arm adopts a low-affinity design to reduce cytokine release, thereby optimising safety while enhancing efficacy. Preclinical studies demonstrate potent cytotoxic activity against primary B cells and B-cell lymphoma cell lines, together with favourable developability properties that support subsequent development of subcutaneous formulations. The programme is currently advancing IND-enabling preclinical studies, and the relevant preclinical data were presented in poster form at the 2026 AACR Annual Meeting. An IND submission is expected in early 2027.

- ***EDP004 (a trispecific T-cell engager targeting CD3/BCMA/GPRC5D)***

  EDP004 binds to BCMA and GPRC5D with high affinity and to CD3 with low affinity, demonstrating excellent target-binding specificity and safety. Preclinical data demonstrate that EDP004 potently kills a variety of multiple myeloma cells with different levels of BCMA and GPRC5D expression while inducing low levels of cytokine release, demonstrating an excellent safety profile and significant potential for the treatment of relapsed/refractory multiple myeloma. In addition, EDP004 possesses favourable developability properties and supports subcutaneous administration. An IND submission is expected by the end of 2026.

Commercialised Products

- ***Vascepa (Icosapent Ethyl IPE)***

  Vascepa is the first triglyceride-lowering therapy approved by both the FDA and the NMPA that can reduce the risk of cardiovascular events. Statin therapy in combination with Vascepa is the only evidence-based treatment regimen for further reducing residual risk in patients with elevated triglyceride levels. IPE has been positively recommended by over 80 international guidelines and consensus statements and 20 domestic guidelines and consensus statements. In June 2026, the American Heart Association (AHA) and other medical societies jointly issued the world's first guideline on cardiovascular-kidney-metabolic (CKM) syndrome, in which IPE was the only therapy recommended for patients with hypertriglyceridaemia. Approximately 60 investigator-initiated trials ("**IITs**") of Vascepa have been initiated to date. In 2026, an IPE IIT initiated by Fuwai Hospital of the Chinese Academy of Medical Sciences received support from the Capital Health Development Research Special Project, and a large-scale real-world study of IPE is expected to be initiated shortly.

- ***Rujianing (Lerociclib)***

  Rujianing is a novel, potent, selective and orally bioavailable CDK4/6 inhibitor that has been launched in China for use in combination with endocrine therapy for the treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer. It was successfully included in the NRDL in December 2025. Following the achievement of the primary endpoint in 2024 by GB491–008, the Phase III clinical trial of Rujianing as first-line treatment for advanced HR+/HER2- breast cancer, the study has continued in accordance with the protocol, and the relevant study data are expected to be presented at SABCS in December 2026.

- ***FPN (Fluticasone Propionate Nebuliser Suspension)***

  FPN is a new-generation nebulised inhaled corticosteroid ("**ICS**") product launched in China for the treatment of mild to moderate asthma in children and adolescents. FPN (generic name: Fluticasone Propionate Nebuliser Suspension) was successfully included in the National Essential Medicines List (2026 Edition) (the "**New National Essential Medicines List**"), which was officially issued by the National Health Commission, the National Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration on 9 July 2026 and will officially take effect on 1 September 2026. The National Essential Medicines List serves as an important basis for the equipping and use of medicines by medical and healthcare institutions and as a fundamental guideline for ensuring the production and supply of medicines for clinical use. Under the relevant requirements governing essential medicines, public medical institutions at all levels throughout China are required to stock and give priority to medicines included in the list. Medicines included in the list have undergone long-term clinical validation, possess proven efficacy and reasonable pricing and demonstrate high clinical application value, reflecting the important role and broad application of essential medicines as key medicines for clinical use. The successful inclusion of FPN in the New National Essential Medicines List represents recognition of its clinical value, therapeutic efficacy and product quality and is of great significance in enhancing the market competitiveness of the Company's respiratory product portfolio.

- ***Vancocin (Vancomycin Hydrochloride for Injection)***

  Vancocin is the originator-branded vancomycin product and is classified as a special-use antibiotic. On 23 June 2026, the National Joint Procurement Office for Centralised Drug Procurement issued the Announcement on the Twelfth Batch of National Centralised Volume-based Drug Procurement (No. 1), pursuant to which vancomycin injections were included within the scope of centralised procurement. On 31 July, the proposed selected results for the twelfth batch of national centralised volume-based drug procurement were announced, and the Group was not among the enterprises proposed to be selected under the volume-based procurement.

The Company cannot guarantee that it will be able to develop, and ultimately market, any of its drug candidates in-development successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the Shares of the Company.

R&D

Our Core Pipeline Products

During the Reporting Period, the Group made significant progress in the development of its core pipeline products and achieved the following R&D milestones:

Clinical-Stage Core Products

GB268: A trispecific antibody targeting PD-1/CTLA-4/VEGF which has entered Phase Ib/II clinical development for the treatment of multiple solid tumours

- **Mechanism and design:** GB268 is a highly innovative trispecific antibody that simultaneously blocks the immunosuppressive signalling pathways of PD-1 and CTLA-4, reverses T-cell exhaustion, promotes T-cell activation and proliferation, and inhibits VEGF-mediated tumour angiogenesis. Through the synergistic effects of multiple mechanisms, GB268 aims to enhance anti-tumour efficacy. Its unique molecular design effectively reduces the risk of immune-related adverse events associated with traditional CTLA-4 inhibitors.

- **Clinical progress:** GB268 received NMPA approval for a first-in-human clinical trial in July 2025. Preliminary data from the 10 mg/kg to 30 mg/kg dose cohorts of the Phase I monotherapy study demonstrated favourable safety and tolerability, encouraging PK/PD profiles and anti-tumour activity across all dose cohorts. The relevant clinical data are expected to be presented at the ESMO annual meeting in October 2026. Based on the Phase I monotherapy study, GB268 received NMPA approval for a Phase Ib/II clinical trial in June 2026 for the treatment of locally advanced unresectable or metastatic breast cancer, including TNBC and HR+/HER2- breast cancer, to explore monotherapy, immunotherapy in combination with chemotherapy and immunotherapy in combination with antibody-drug conjugates. Enrolment in a Phase III clinical study is planned to commence in the fourth quarter of 2027. GB268 will subsequently undergo Phase II clinical studies as monotherapy or in combination therapy in multiple solid tumours, including but not limited to advanced breast cancer, non-small cell lung cancer, colorectal cancer, biliary tract cancer and other solid tumours.

EDP167: An siRNA therapeutic targeting hepatic ANGPTL3 which has initiated Phase II clinical development for the treatment of HoFH and mixed dyslipidaemia

- **Mechanism and design:** ANGPTL3 is secreted by the liver and inhibits the activity of both lipoprotein lipase and endothelial lipase, thereby regulating the metabolism of multiple atherogenic lipoproteins. Genetic studies indicate that individuals carrying loss-of-function mutations in ANGPTL3 exhibit a significantly reduced risk of atherosclerotic cardiovascular disease. EDP167 employs an N-acetylgalactosamine ("**GalNAc**") conjugate to target hepatocytes, enabling specific degradation of hepatic ANGPTL3 mRNA and inhibition of ANGPTL3 protein expression, thereby achieving dual reductions in low-density lipoprotein cholesterol ("**LDL-C**") and triglycerides ("**TG**").

- **Completion of Phase I clinical study:** In June 2025, EDP167 received approval from the NMPA to commence clinical trials. In July 2025, the Group initiated a randomised, double-blind, placebo-controlled, single-ascending-dose (SAD) Phase I clinical study in healthy volunteers and subjects with mild dyslipidaemia. The study comprised five dose cohorts with a total of 40 subjects enrolled, and the last subject last visit was completed in December 2025. The study systematically evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous administration of EDP167 across different dose levels. The results demonstrated overall favourable safety and tolerability and the ability to comprehensively improve the atherogenic lipid profile, including LDL-C, TG, non-high-density lipoprotein cholesterol ("**non-HDL-C**"), apolipoprotein B ("**apoB**") and remnant cholesterol ("**RC**"), with therapeutic effects persisting for 85 days after administration. These results indicate that EDP167 has the potential to be among the best-in-class therapies targeting ANGPTL3 and support its further clinical evaluation. Data from the Phase I study will be presented at the ESC Congress on 30 August, 2026.

- **Initiation of Phase II clinical study:** In February 2026, a multicentre, dose-exploration, open-label Phase II clinical study was initiated in adult patients with HoFH. The study aims to evaluate the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in LDL-C levels from baseline after 24 weeks of treatment. Enrolment of the last subject was completed in June 2026, and assessment of the primary endpoint is expected to be completed in the fourth quarter of 2026. Enrolment in the Phase III study is expected to commence in the first quarter of 2027, with assessment of the Phase III primary endpoint expected to be completed in the fourth quarter of 2027. The mechanism of action of EDP167 overcomes the limitations of conventional lipid-lowering therapies that rely on low-density lipoprotein receptor ("**LDLR**") function, providing an important innovative treatment option with broad clinical application potential for patients with dyslipidaemia disorders such as HoFH. In addition, enrolment in a Phase II clinical study in patients with mixed dyslipidaemia is expected to commence in the fourth quarter of 2026, with assessment of the Phase II primary endpoint expected to be completed in the fourth quarter of 2027.

GB261 (CND261): A bispecific T-cell engager targeting CD3/CD20 for B-cell lymphoma and autoimmune diseases

- **Mechanism and design:** GB261 is a highly differentiated CD3/CD20 bispecific T-cell engager featuring a low-affinity CD3 design intended to mitigate safety risks associated with cytokine release.

- **Clinical outcomes:** A Phase I/II dose escalation study has been completed, demonstrating an excellent safety profile and a highly favourable balance between safety and efficacy in patients with diffuse large B-cell lymphoma ("**DLBCL**") and follicular lymphoma ("**FL**").

- **Latest developments in the collaboration with Candid:** On 3 May 2026, UCB entered into a merger agreement with Candid, the licensee of the overseas rights to GB261, pursuant to which UCB would acquire Candid. On 17 June 2026, UCB announced the successful completion of its acquisition of Candid. On 16 July 2026, the Group received proceeds of US$48,419,599.63 as partial consideration to which it was entitled for the disposal of its entire equity interest in Candid and is entitled, in accordance with the merger agreement, to a pro rata share of clinical development milestone payments of up to US$200 million and other potential future payments. Meanwhile, the Group remains entitled to receive milestone payments in connection with the subsequent development of GB261, with aggregate milestone payments of up to US$443 million, and tiered royalties on future net sales at rates ranging from single-digit to double-digit percentages.

Preclinical Assets

The Group continues to deepen its pipeline strategy, with multiple bispecific and multispecific antibody candidates as well as small nucleic acid candidates currently in the discovery and preclinical stages. These programmes focus on addressing significant unmet clinical needs and aim to overcome the limitations and technical bottlenecks of existing therapies, thereby continuously building a differentiated and competitive early-stage R&D pipeline.

EDP001: A highly innovative tetraspecific T-cell engager targeting CD3/CD19/CD19/BCMA for the treatment of multiple B-cell-driven autoimmune diseases

- **Mechanism and design:** EDP001 is a tetraspecific T-cell engager specifically engineered for autoimmune diseases, designed to enhance safety while achieving deep B-cell depletion to enable long-term disease remission. EDP001 exhibits high-specificity and high-affinity binding to both BCMA and CD19. Its unique dual-epitope CD19 binding design significantly increases binding affinity to CD19+ B cells, enabling highly efficient B-cell depletion. Targeting BCMA facilitates the elimination of autoantibody-secreting plasma cells, while the CD3 arm adopts a low-affinity design to reduce cytokine release.

- Preclinical data demonstrate potent cytotoxic activity against primary B cells and B-cell lymphoma cell lines, highlighting its therapeutic potential in refractory autoimmune diseases and B-cell malignancies. The relevant preclinical data were presented in poster form at the 2026 AACR Annual Meeting. In addition, its favourable developability data support subsequent development of subcutaneous formulations. The programme is currently advancing IND-enabling preclinical studies, and an IND submission is expected in early 2027.

EDP004: A trispecific T-cell engager targeting CD3/BCMA/GPRC5D for the treatment of multiple myeloma

- **Mechanism and design:** EDP004 is an internally developed trispecific T-cell engager targeting CD3, BCMA and GPRC5D. The molecule binds to BCMA and GPRC5D with high affinity and to CD3 with low affinity, demonstrating excellent target-binding specificity and safety.

- Preclinical data demonstrate that EDP004 potently kills a variety of multiple myeloma cells with different levels of BCMA and GPRC5D expression while inducing low levels of cytokine release, demonstrating an excellent safety profile and significant potential for the treatment of relapsed/refractory multiple myeloma. In addition, EDP004 possesses favourable developability properties and supports subcutaneous administration. An IND submission is expected by the end of 2026.

Our Platform Development

- **Large-Molecule Antibody Drug Development Platform**

  We have successfully established a comprehensive and highly efficient large-molecule antibody drug development platform integrating discovery, innovation and application. The platform integrates an experienced antibody R&D team, cutting-edge technologies and artificial intelligence, and possesses end-to-end capabilities spanning target discovery, early-stage antibody screening, bispecific and multispecific antibody design and optimisation, in vitro activity validation, in vivo efficacy and pharmacokinetic analysis, through to developability assessment. The R&D team has extensive experience across multiple molecular formats, including bispecific and multispecific antibodies, T-cell engagers, antibody-drug conjugates and nanobodies. Based on target biology and disease mechanisms, the team is able to design optimal molecular formats and pursue differentiated innovation throughout the drug development process and across multiple dimensions, with a focus on achieving tangible clinical benefits. Multiple programmes in the early-stage pipeline are currently at the drug discovery stage. It is expected that two to four preclinical candidate compounds will be completed by 2026, covering oncology, autoimmune diseases and chronic inflammation. These programmes are dedicated to continuous innovation to address significant unmet clinical needs and will further diversify the Group's mid – to long-term R&D pipeline and product portfolio.

- **Small Nucleic Acid Drug Development Platform**

  The Group has established an in-house R&D platform for small nucleic acid therapeutics, laying the foundation for future competitiveness in chronic disease areas. The platform encompasses various classes of small nucleic acid therapeutics, including siRNA and ASO, and is built upon three core technology modules comprising sequence design, chemical modification and targeted delivery. The pipeline strategy is clinically driven and integrates target biological mechanisms with the technical characteristics of small nucleic acid therapeutics, covering chronic disease areas such as cardiovascular, metabolic, autoimmune and liver diseases. A dual-target small nucleic acid platform has also been developed, which simultaneously and precisely silences two key pathogenic targets to achieve mechanistic synergy and additive therapeutic effects. Multiple programmes in the early-stage pipeline are currently at the drug discovery stage, and the nomination of preclinical candidate molecules for two programmes is expected to be completed in 2026.

FINANCIAL REVIEW

As disclosed in 2025 annual report, on 30 December 2025 (the "**Merger Date**"), the Company completed a very substantial acquisition and reverse takeover with Edding Group Company Limited ("**Edding**"), a company incorporated in the Cayman Islands with limited liability, which involved a new listing application (the "**Merger**"). The Company has applied the reverse acquisition accounting under HKFRS 3. Accordingly, the consolidated financial statements have been prepared as a continuation of the consolidated financial statements of Edding and its subsidiaries ("**Edding Group**"). The results of the Company and its original subsidiaries have been consolidated into the Edding Group's consolidated financial statements since the Merger Date. Comparative information presented in the interim condensed consolidated financial statements has been restated to reflect the financial performance of Edding Group prior to the completion of the Merger.

Selected Consolidated Income Statement Items

	Notes	Six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Audited)
			(Restated)
Revenue	*1*	**872,732**	1,135,542
Cost of sales	*2*	**(294,645)**	(375,925)
Gross profit	*3*	**578,087**	759,617
Other income and gains		**12,758**	13,351
Selling and distribution expenses		**(222,605)**	(236,758)
Administrative expenses		**(115,481)**	(126,271)
Research and development expenses	*4*	**(107,735)**	(72,713)
Amortisation of distribution rights, medicine licenses and trademark		**(34,526)**	(37,000)
Reversal of impairment losses/(impairment losses) on financial assets, net		**1,244**	(17)
Other expenses	*5*	**(75,217)**	(29,076)
Finance costs, net	*6*	**(77,660)**	(93,975)
(LOSS)/PROFIT BEFORE TAX		**(41,135)**	177,158
Income tax expense	*7*	**(24,741)**	(62,592)
(LOSS)/PROFIT FOR THE PERIOD		**(65,876)**	114,566

Consolidated Statements of Financial Position

	Notes	**30 June 2026** ***RMB'000*** **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property and equipment	*8*	**272,882**	283,673
Prepayments, other receivables and other assets		**191,197**	191,245
Deferred tax assets		**80,925**	81,824
Right-of-use assets		**67,919**	54,929
Goodwill	*9*	**399,224**	399,224
Other intangible assets	*9*	**3,087,630**	3,238,760
Equity investment designated at fair value through other comprehensive income	*10*	**–**	102,316
Financial asset at fair value through profit or loss		**49,791**	50,000
Total non-current assets		**4,149,568**	4,401,971
CURRENT ASSETS			
Inventories		**437,470**	432,272
Trade receivables	*11*	**143,552**	631,441
Prepayments, other receivables and other assets		**444,726**	79,455
Amounts due from a related party		**2,075**	2,075
Pledged deposits		**331**	393
Cash and cash equivalents	*12*	**913,003**	1,054,935
Total current assets		**1,941,157**	2,200,571
CURRENT LIABILITIES			
Trade payables		**117,037**	322,771
Other payables and accruals	*13*	**616,485**	707,700
Refund liabilities		**–**	21,876
Interest-bearing bank and other borrowings	*14*	**1,123,240**	1,065,708
Dividends payable		**2,621**	2,695
Tax payables		**57,505**	71,124
Lease liabilities		**19,585**	19,090
Total current liabilities		**1,936,473**	2,210,964
NET CURRENT ASSETS/(LIABILITIES)		**4,684**	(10,393)
TOTAL ASSETS LESS CURRENT LIABILITIES		**4,154,252**	4,391,578

Consolidated Statements of Financial Position (Continued)

	Notes	**30 June 2026** ***RMB'000*** **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowings	*14*	**–**	374,517
Deferred tax liabilities		**101,167**	100,636
Lease liabilities		**39,609**	27,186
Amounts due to related parties		**314**	588
Other liabilities		**35,846**	37,676
Total non-current liabilities		**176,936**	540,603
Net assets		**3,977,316**	3,850,975
EQUITY			
Equity attributable to owners of the parent			
Share capital		**280**	280
Reserves		**3,979,866**	3,853,549
		3,980,146	3,853,829
Non-controlling interests		**(2,830)**	(2,854)
Total equity		**3,977,316**	3,850,975

1. Revenue

The Group's revenue decreased by approximately 23.1% from RMB1,135.5 million for the six months ended 30 June 2025 to RMB872.7 million for the Reporting Period.

The following table sets forth the breakdown of the Group's gross revenue by products for the periods indicated, and a reconciliation of gross revenue to net revenue. The Group presents revenue by product on a gross basis, which is calculated based on revenue before deduction of sales rebates and sales tax. Sales rebates and sales tax are not allocated to each product, and therefore the breakdown of revenue by product does not take into account such items.

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
		(Restated)
Originator-branded products		
Vancocin	**461,064**	716,719
Ceclor	**270,168**	264,347
FPN	**45,977**	46,837
Subtotal of originator-branded products	**777,209**	1,027,903
Innovative products		
Vascepa	**85,878**	72,259
Rujianing	**25,124**	–
Mulpleta	**4,722**	3,797
Subtotal of innovative products	**115,724**	76,056
Other products[(1)]	**24,409**	38,939
Service income[(2)]	**–**	22,594
Gross revenue	**917,342**	1,165,492
Less:		
Sales rebates	**(40,286)**	(26,262)
Sales tax	**(4,324)**	(3,688)
Revenue	**872,732**	1,135,542

(1) Represents Recormon for the six months ended 30 June 2026 and 2025.

(2) Represents revenue from business support services for GB491 and GB268 since the first half of 2025.

The gross sales revenue from the Group's innovative drug increased by 52.2% from RMB76.1 million for the six months ended 30 June 2025 to RMB115.7 million for the Reporting Period. Of this amount, RMB85.9 million was derived from Vascepa, representing an increase of RMB13.6 million, or 18.8%, as compared with the six months ended 30 June 2025, primarily attributable to the Group's enhanced sales and marketing efforts. The remaining growth was mainly contributed by Rujianing, a new innovative drug launched in late 2025, which generated gross sales revenue of RMB25.1 million during the Reporting Period.

In addition, Ceclor, the Group's originator-branded drug, recorded gross sales revenue of RMB270.2 million for the Reporting Period, representing an increase of RMB5.8 million, or 2.2%, as compared with the six months ended 30 June 2025.

On the other hand, gross sales revenue from Vancocin decreased by RMB255.7 million, or 35.7%, for the Reporting Period as compared with the previous corresponding period. The decrease was mainly due to the impact of China's Centralized Drug Procurement scheme. Although the procurement will only take effect from the second half of 2026, the anticipatory response has already adversely affected sales during the Reporting Period.

2. Cost of Sales

The Group's cost of sales decreased from RMB375.9 million for the six months ended 30 June 2025 to RMB294.6 million for the Reporting Period, in line with the Group's revenue trends.

3. Gross Profit and Gross Profit Margin

The Group's gross profit decreased from RMB759.6 million for the six months ended 30 June 2025 to RMB578.1 million for the Reporting Period, in line with the Group's revenue trends. The overall gross profit margin was 66.2% for the Reporting Period, largely in line with 66.9% for the six months ended 30 June 2025.

4. Research and Development Expenses

The Group's R&D expenses increased by 48.2% from RMB72.7 million for the six months ended 30 June 2025 to RMB107.7 million for the Reporting Period, primarily due to the increase in new drug development costs and testing expenses as a result of the advancement of the Company's core products at clinical stage, including GB268 and EDP167, as well as the development of new projects (including biologics and product localisation).

5. Other Expense

The Group's other expenses increased by 158.7% from RMB29.1 million for the six months ended 30 June 2025 to RMB75.2 million for the Reporting Period, primarily due to an impairment loss of RMB44.8 million related to an exclusive commercialisation right of Jing Zhu Da.

6. Finance Costs, Net

The Group's finance costs, net, decreased by 17.4% from RMB94.0 million for the six months ended 30 June 2025 to RMB77.7 million for the Reporting Period, primarily due to the decrease of interest expense of loans. In the Reporting Period, part of the Company's loans were repaid, which further reduced the net finance costs.

7. Income Tax Expense

The Group's income tax expense decreased from RMB62.6 million for the six months ended 30 June 2025 to RMB24.7 million for the Reporting Period, primarily due to the lower profit before tax for the Reporting Period caused by changing market conditions and operational fluctuations.

8. Property, Plant and Equipment

The Group's property, plant and equipment mainly consist of the manufacturing and R&D assets in our factory in Suzhou. The Group's property, plant and equipment decreased from RMB283.7 million as at 31 December 2025 to RMB272.9 million as at 30 June 2026, as the result of depreciation.

9. Other Intangible Assets and Goodwill

The other intangible assets of the Group decreased by RMB151.2 million from RMB3,238.8 million as at 31 December 2025 to RMB3,087.6 million as at 30 June 2026, as the result of amortization and impairment related to an exclusive commercialisation rights of Jing Zhu Da. The goodwill of the Group remained at RMB399.2 million as at 30 June 2026.

10. Equity Investment Designated at Fair Value through Other Comprehensive Income

The Group's equity investments at fair value through other comprehensive income decreased from RMB102.3 million as at 31 December 2025 to nil as at 30 June 2026, primarily due to the disposal of the Group's entire equity investment in Candid Therapeutics, Inc. pursuant to its merger with UCB. The group had been entitled to receive a cash consideration of approximately RMB327.2 million in relation to the disposal of unlisted equity investment, which had been received on 16 July 2026.

11. Trade Receivables

The Group's trade receivables decreased from RMB631.4 million as at 31 December 2025 to RMB143.6 million as at 30 June 2026. This was mainly due to the collection of receivables from distributors and the decrease on sales during the six months ended 30 June 2026. The accounts receivable are mainly due from large domestic distributors with good credit, and the Directors are of the view that no significant credit risk exists. By the end of 31 July 2026, 42.5% of the trade receivables as at 30 June 2026 had been settled.

12. Cash and Cash Equivalents

Our cash and cash equivalents decreased by RMB141.9 million, or 13.5%, from RMB1,054.9 million as at 31 December 2025 to RMB913.0 million as at 30 June 2026. The decrease was mainly attributable to the repayment of the borrowings and the increase in R&D expenditure, partially offset by improved collection of accounts receivables.

13. Other Payables and Accruals

Our other payables and accruals decreased from RMB707.7 million as at 31 December 2025 to RMB616.5 million as at 30 June 2026. This was primarily attributable to a decrease of RMB59.7 million in payroll payables which was due to the decrease of bonuses, and a decrease of RMB29.9 million in other taxes payables which was due to the decrease of VAT payables.

14. Interest-bearing Bank Borrowings

Our long-term and short-term interest-bearing bank borrowings as at 30 June 2026 decreased by RMB317.0 million compared to 31 December 2025, which was mainly due to the repayment and extension of certain bank borrowings.

15. Key Financial Ratios

The following table sets forth the key financial ratios for the details indicated:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Current ratio[1]	**100.2%**	99.5%
Quick ratio[2]	**74.4%**	78.3%
Gearing ratio[3]	**34.7%**	41.7%

Notes:

1. Current ratio is calculated using current assets divided by current liabilities as at the same date.

2. Quick ratio is calculated using current assets less inventories and prepayments and divided by current liabilities as at the same date.

3. Gearing ratio is calculated using total liabilities divided by total assets as at the same date.

16. Material Acquisitions and Disposals and Future Plans for Material Investments

On 16 July 2026, the Company received proceeds of US$48,419,599.63 from the disposal of its entire equity interest in Candid Therapeutics, Inc. (the "**Disposal**"). The Disposal arises from a merger agreement entered into on 3 May 2026 among others, UCB, its merger subsidiary, and Candid, pursuant to which UCB's merger subsidiary will merge with and into Candid, with Candid continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of UCB (the "**Merger**"). As a stockholder of Candid bound by a voting agreement among Candid and its stockholders, the Company was contractually obligated to vote in favour of the Merger. Upon consummation of the Merger, all of the Company's shares in Candid will automatically be converted into the right to receive cash consideration, together with all other Candid stockholders (other than dissenting stockholders). For details, please refer to the Company's announcement dated 16 July 2026.

Save as disclosed above, the Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies during the Reporting Period and up to the date of this announcement.

As at the date of this announcement, our Group does not have any concrete committed plans for material investments and capital assets for disclosure.

17. Contingent Liabilities

A subsidiary of the Group is currently a defendant in a lawsuit brought by a party alleging that the subsidiary breached the supply agreement and supplemental agreement. The Directors, based on the advice from the Group's legal counsel, believe that the subsidiary has a valid defence against the allegation and, accordingly, the Group has not provided for any claim arising from the litigation.

18. Liquidity and Source of Funding and Borrowing

Our management monitors and maintains a level of cash and bank balances deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flow. We rely on operating cash flows from daily business activities and financing activities as the major source of liquidity. As at 30 June 2026, the short-term borrowings from bank was RMB1,123.2 million (as at 31 December 2025: RMB1,065.7 million).

Our cash and cash equivalents decreased to RMB913.0 million as at 30 June 2026 from RMB1,054.9 million as at 31 December 2025, mainly due to the repayment of the borrowings and the increase in R&D expenditure, partially offset by improved collection of accounts receivables.

19. Non-HKFRS Measures

To supplement the Group's consolidated financial statements which are presented in accordance with HKFRS, the Company presents EBITDA (non-HKFRS measure), adjusted EBITDA (non-HKFRS measure) and adjusted net profit (non-HKFRS measure), as additional financial measures, which are not required by, or presented in accordance with HKFRS.

The Group believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Group's management and investors may benefit from referring to these adjusted financial measures in assessing the Group's financial performance by eliminating the impact of certain unusual, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group's core business. The Group's management believes that these non-HKFRS financial measures are widely accepted and adopted in the industry in which the Group operates.

The adjusted financial measures should not be considered in isolation or construed as an alternative to net profit or any measure of performance. Investors are encouraged to review our historical non-HKFRS financial measures together with the most directly comparable HKFRS measures. The adjusted financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

Additional information is provided below to reconcile EBITDA (non-HKFRS measure), adjusted EBITDA (non-HKFRS measure) and adjusted net profit (non-HKFRS measure) to the corresponding measures under HKFRS.

EBITDA, adjusted EBITDA and adjusted net profit (non-HKFRS measure)

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
		(Restated)
Net (loss)/profit	**(65,876)**	114,566
Add:		
Depreciation of property, plant and equipment	**18,407**	15,543
Depreciation of right-of-use assets	**10,410**	11,557
Amortisation of other intangible assets	**106,390**	91,311
Finance costs, net	**77,660**	93,975
Income tax expense	**24,741**	62,592
EBITDA (non-HKFRS measure)	**171,732**	389,544
Add:		
Share-based payment expenses	**33,029**	32,832
Transaction expenses in connection with the reverse takeover	**–**	10,222
Adjusted EBITDA (non-HKFRS measure)	**204,761**	432,598

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
		(Restated)
Net (loss)/profit	**(65,876)**	114,566
Add:		
Share-based payment expenses	**33,029**	32,832
Transaction expenses in connection with the reverse takeover	**–**	10,222
Adjusted net (loss)/profit (non-HKFRS measure)	**(32,847)**	157,620

Notes:

(1) EBITDA (non-HKFRS measure) represents net (loss)/profit excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortisation of other intangible assets, finance costs, net and income tax expense.

(2) Adjusted EBITDA (non-HKFRS measure) represents net (loss)/profit excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortisation of other intangible assets, finance costs, net, income tax expense, share-based payment expenses and transaction expenses in connection with the reverse takeover.

(3) Adjusted net (loss)/profit (non-HKFRS measure) represents net (loss)/profit excluding share-based payment expenses and transaction expenses in connection with the reverse takeover.

(4) Depreciation and amortisation exclude those allocated to and form part of the costs of inventories before they are sold.

20. Employees and Remuneration

As at 30 June 2026, the Group had 1,499 employees. Substantially all of the Group's employees are based in China.

The total remuneration cost incurred by the Group for the Reporting Period was RMB266,640,000, as compared to RMB248,180,000 for the six months ended 30 June 2025.

Our employees' remuneration comprises salaries, bonuses, social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees. As at 30 June 2026, we had complied with all statutory social security insurance fund and housing fund obligations applicable to us under Chinese laws in all material aspects.

Prior to the Merger Closing, the Company adopted a pre-IPO share option plan (the "**Pre-IPO Share Option Plan**"), a post-IPO share option plan (the "**Post-IPO Share Option Plan**"), a 2021 restricted share unit plan (the "**2021 RSU Plan**"), a 2023 share option plan (the "**2023 Share Option Plan**") and a 2023 restricted share unit plan (the "**2023 RSU Plan**") to provide incentives or rewards to eligible participants for their contribution to the Group. The Post-IPO Share Option Plan and the 2021 RSU Plan were terminated on 27 October 2023. All outstanding share options (to the extent not already exercised) granted under the Post-IPO Share Option Plan shall continue to be valid and exercisable in accordance with the terms of the Post-IPO Share Option Plan and the relevant grant agreements. All unvested restricted share units granted under the

2021 RSU Plan shall continue to be valid and shall vest in accordance with the terms of the 2021 RSU Plan and the relevant grant agreements. The 2023 Share Option Plan and the 2023 RSU Plan were terminated in December 2025 to the effect that no further share options and RSUs may be granted under the 2023 Share Option Plan and the 2023 RSU Plan, but all other terms of the 2023 Share Option Plan and the 2023 RSU Plan shall remain in full force and effect.

The Company has adopted a one-off share option plan (the "**One-off Share Option Plan**"), in replacement of the Target Share Option Scheme effective upon the Merger Closing.

Please refer to the section headed "Statutory and General Information – D. Share Option Schemes" in Appendix VI to the Company's circular dated 5 December 2025 for further details.

During the Reporting Period, the Group did not experience significant labour disputes or difficulties in recruiting employees.

INTERIM DIVIDEND

The Board did not recommend the distribution of an interim dividend for the six months ended 30 June 2026.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated under the laws of the Cayman Islands on 10 April 2017 as an exempted company with limited liability, and the shares of the Company were listed on the Stock Exchange on 7 October 2020 (the "**Listing**").

1. Compliance with the Corporate Governance Code

The Board is committed to establishing and maintaining high standards of corporate governance so as to enhance corporate transparency and protect the interests of the Shareholders. The Company devotes to best practice on corporate governance, and to comply with the extent practicable, with the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 of the Listing Rules.

During the Reporting Period, to the best knowledge of the Board, the Company has complied with all the code provisions in the CG Code, save for deviation from code provision C.2.1 as explained below:

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separated and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing.

Since the Merger Closing, the roles of the Chairman and chief executive have been performed by Mr. Ni Xin ("**Mr. Ni**"). In view of Mr. Ni's substantial contribution to the Group and his extensive experience, we consider that having Mr. Ni acting as both our Chairman and chief executive will provide strong and consistent leadership to the Group and facilitate the efficient execution of our business strategies. We consider it appropriate and beneficial to our business development and prospects that Mr. Ni will act as both our Chairman and chief executive, and therefore will not propose to separate the functions of Chairman and chief executive.

While this would constitute a deviation from code provision C.2.1 of Part 2 of the Corporate Governance Code, the Board believes that this structure will not impair the balance of power and authority between the Board and the management of the Group, given that: (i) there are sufficient checks and balances in the Board, as a decision to be made by our Board requires approval by at least a majority of our Directors, and our Board will comprise three independent non-executive Directors, which is in compliance with the requirement under the Listing Rules; (ii) Mr. Ni and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that he acts for the benefit and in the best interests of our Company and will make decisions for the Group accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which will continue to comprise experienced and high calibre individuals who meet regularly to discuss issues affecting the operations of our Company. Moreover, the overall strategic and other key business, financial, and operational policies of the Group are made collectively after thorough discussion at both Board and senior management levels. The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of Chairman and chief executive is necessary.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

2. Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules (the "**Model Code**") to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

Specific enquiry has been made to all the Directors and they have confirmed that they have complied with the required standards as set out in the Model Code throughout the Reporting Period. No incident of non-compliance of the Model Code by the relevant employees was noted by the Company throughout the Reporting Period.

3. Review of Unaudited Interim Consolidated Results

The Company has established the Audit Committee with written terms of reference in accordance with the Listing Rules. The Audit Committee comprises three members, namely Ms. Zheng Jingjing, Mr. Yu Tieming and Dr. Xu Qing, with Ms. Zheng Jingjing (being the Company's independent non-executive Director with appropriate professional qualifications) as the chairperson of the Audit Committee.

The Audit Committee has reviewed the unaudited interim condensed consolidated financial information of the Group for the six months ended 30 June 2026 and this announcement. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal financial reporting matters.

In addition, the independent auditor of the Company, Ernst & Young, has reviewed the unaudited interim financial information of the Group for the six months ended 30 June 2026 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

4. Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period, we repurchased 23,293,500 Shares on the Stock Exchange at an aggregate amount of approximately HK$69,607,190, all of which are held as treasury Shares (as defined under the Listing Rules). The Company has not yet determined on the intended use of the treasury Shares and will utilise them as permitted under the Listing Rules, subject to, market conditions and its capital management needs.

Details of the Shares repurchased during the Reporting Period are as follows:

Month of repurchase	Number of Shares repurchased on the Stock Exchange	Price paid per Share		Aggregate purchase price
		Highest *(HK$)*	Lowest *(HK$)*	*(HK$)*
January 2026	2,973,500	2.56	2.35	7,488,205
February 2026	7,961,000	3.26	2.52	22,425,990
March 2026	279,500	2.67	2.53	725,580
April 2026	12,079,500	3.55	2.70	38,967,415

Save as disclosed above, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares) during the Reporting Period. As of 30 June 2026, the Company held 23,293,500 treasury Shares.

5. Material Litigation

During the Reporting Period and as at the date of this announcement, the Company was not involved in any material litigations or arbitrations and the Directors are not aware of any material litigations or claims that are pending or threatened against the Group.

6. Significant Events after the Reporting Period

On 16 July 2026, the Company received proceeds of US$48,419,599.63 from the Disposal. For further details, please refer to the sections headed "Management Discussion and Analysis – Material Acquisitions and Disposals and Future Plans for Material Investments" in this announcement above.

On 5 August 2026, the Company was informed in writing by Taizhou EOC Pharma Co., Ltd. (the "**Taizhou EOC**") that Syndax Pharmaceuticals, Inc. ("**Syndax**") has issued a notice to EOC Pharma (Hong Kong) Limited ("**EOC HK**") terminating the original license agreement dated 18 April 2013 entered into between Syndax and EOC HK (the "**Original License Agreement**"). As a result of the termination of the Original License Agreement, EOC HK no longer holds any rights to use the relevant patents and intellectual property in respect of the development and commercialisation of Jing Zhu Da, and accordingly no longer has any rights that can be sub-licensed to Taizhou EOC, which in turn means Taizhou EOC is unable to perform its obligations under the sub-

license agreement dated 9 May 2023 (the "**2023 Sub-License Agreement**") to grant Suzhou Eddingpharm the relevant sub-licensed rights. Accordingly, the 2023 Sub-License Agreement and the continuing connected transactions contemplated thereunder can no longer be performed. For details, please refer to the Company's announcement dated 5 August 2026.

Save as disclosed herein, the Directors are not aware of any significant event requiring disclosure that has taken place subsequent to 30 June 2026 and up to the date of this announcement.

7. Use of Net Proceeds from Global Offering

The Company's shares were listed on the Stock Exchange on 7 October 2020 with a total of 129,683,500 offer shares (including shares issued as a result of the partial exercise of the over-allotment option) issued and the net proceeds raised during the global offering were approximately HKD2,923 million (equivalent to approximately RMB2,536 million) (the "**Net Proceeds**"). As set out in the Company's announcement dated 28 October 2020, the Company shall utilise the additional Net Proceeds raised from the partial exercise of the over-allotment option on a pro-rata basis for the purposes set out in the Prospectus. There has been no issue for cash of equity securities by the Company during the Reporting Period.

As at 30 June 2026, the Company had utilised RMB2,096.2 million of Net Proceeds in accordance with the plan disclosed in the Prospectus, the change in use of net proceeds from the global offering allocated to the different stages of each of our Core Products, other key products and other pipeline products as disclosed in the interim results announcement of the Company for the six months ended 30 June 2022, and the further change in use of Net Proceeds as disclosed in the interim results announcement of the Company for the six months ended 30 June 2023 ("**2023 Interim Results Announcement**").

As at 30 June 2026, approximately RMB439.8 million of the Net Proceeds remained unutilised and will be allocated and used in accordance with the purposes and proportions as set out in the 2023 Interim Results Announcement. The Company will gradually utilise the residual amount of the Net Proceeds in accordance with such intended purposes depending on actual business needs. The expected timeline for utilising the Net Proceeds is based on the best estimation of future progress of regulatory approvals and market conditions made by our Company and subject to changes in accordance with relevant clinical development, our actual business operations and markets conditions.

Details of the use of the Net Proceeds are set out as below.

	Revised Allocation of Net Proceeds[Note 1] *RMB million*	**Unutilised Net Proceeds as at 1 January 2026** *RMB million*	**Net Proceeds utilised during the six months ended 30 June 2026** *RMB million*	**Utilised Net Proceeds as at 30 June 2026** *RMB million*	**Unutilised Net Proceeds as at 30 June 2026** *RMB million*	**Expected timeline to fully utilise the remaining unutilised Net Proceeds**[Note 2]
Fund research and development activities of GB491, GB261 and GB263, including ongoing and planned clinical trials, indication expansion and preparation for registration filings, and commercialisation	1,329.2	309.1	6.3	1,026.4	302.8	On or before 31 December 2026
Fund the expansion of our drug pipeline	253.6	132.4	–	121.2	132.4	On or before 31 December 2026
Fund ongoing and planned clinical trials, preparation for registration filings, and commercialisation of GB226 (including combination trials with GB492), GB242 and the other drug candidates in our pipeline	699.6	18.6	14.0	695.0	4.6	On or before 31 December 2026
General corporate purposes[Note 3]	253.6	46.2	46.2	253.6	–	On or before 31 December 2026
Total	**2,536.0**	**506.3**	**66.5**	**2,096.2**	**439.8**	

Notes:

1. The Net Proceeds figure has been translated to Renminbi for the allocation and the utilisation calculation, and has been adjusted slightly due to the fluctuation of the foreign exchange rates since the Listing.

2. The expected timeline for fully utilising the remaining unutilised Net Proceeds is based on the best estimation of the future market conditions made by the Group. It may be subject to change based on the current and future development of market conditions.

3. The Net Proceeds allocated for general corporate purposes and utilised during the year ended 31 December 2025 and the six months ended 30 June 2026 were solely for employee remuneration.

The table below specifies further breakdown for the Net Proceeds to be allocated to different stages of our products and their utilisation during the Reporting Period.

	Revised Allocation of Net Proceeds to Each Stage[(Note 1)]							
	Pre-clinical *RMB million*	**Clinical** *RMB million*	**Commercialisation (including registration)** *RMB million*	**Unutilised Net Proceeds as at 1 January 2026** *RMB million*	**Net Proceeds utilised during the six months ended30 June 2026** *RMB million*	**Utilised Net Proceeds as at 30 June 2026** *RMB million*	**Unutilised Net Proceeds as at 30 June 2026** *RMB million*	**Expected timeline to fully utilise the remaining unutilised Net Proceeds[(Note 2)]**
GB491	–	736.4	100	41.8	5.5	800.1	36.3	On or before 31 December 2026
GB261	55.8	277.1	–	179.6	0.7	154.0	178.9	On or before 31 December 2026
GB263	45.8	114.1	–	87.7	0.1	72.3	87.6	On or before 31 December 2026
GB242, GB226, GB492 and other products[(Note 3)]	23.9	549.7	126	18.6	14.0	695.0	4.6	On or before 31 December 2026
Total				**327.7**	**20.3**	**1,721.4**	**307.4**	

Notes:

1. The Net Proceeds figure has been translated to Renminbi for the allocation and the utilisation calculation, and has been adjusted slightly due to the fluctuation of the foreign exchange rates since the Listing.

2. The expected timeline for fully utilising the remaining unutilised Net Proceeds is based on the best estimation of the future market conditions made by the Group. It may be subject to change based on the current and future development of market conditions.

3. Other products include GB221, GB223, GB241, GB251, GB262, and GB264. The Company will make investment on those products according to the current and future development conditions and market competition environment.

CONSOLIDATED FINANCIAL STATEMENTS

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026

	Notes	**2026** ***RMB'000*** **(Unaudited)**	2025 *RMB'000* (Audited) (Restated)
Revenue	*3*	**872,732**	1,135,542
Cost of sales		**(294,645)**	(375,925)
Gross profit		**578,087**	759,617
Other income and gains		**12,758**	13,351
Selling and distribution expenses		**(222,605)**	(236,758)
Administrative expenses		**(115,481)**	(126,271)
Research and development expenses		**(107,735)**	(72,713)
Amortisation of distribution rights, medicine licenses and trademark		**(34,526)**	(37,000)
Reversal of impairment losses/(impairment losses) on financial assets, net		**1,244**	(17)
Other expenses		**(75,217)**	(29,076)
Finance costs, net		**(77,660)**	(93,975)
(LOSS)/PROFIT BEFORE TAX		**(41,135)**	177,158
Income tax expense	*4*	**(24,741)**	(62,592)
(LOSS)/PROFIT FOR THE PERIOD		**(65,876)**	114,566
Attributable to:			
Owners of the parent		**(65,836)**	114,566
Non-controlling interests		**(40)**	–
		(65,876)	114,566

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS (CONTINUED)

For the six months ended 30 June 2026

	Notes	**2026** ***RMB'000*** **(Unaudited)**	2025 *RMB'000* (Audited) (Restated)
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic			
– For (loss)/profit for the period		**RMB(3.3) cents**	RMB6.9 cents
Diluted			
– For (loss)/profit for the period		**RMB(3.3) cents**	RMB6.9 cents

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	2026 *RMB'000* **(Unaudited)**	2025 *RMB'000* (Audited) (Restated)
(LOSS)/PROFIT FOR THE PERIOD	**(65,876)**	114,566
OTHER COMPREHENSIVE (LOSS)/INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences:		
Exchange differences on translation of foreign operations	**(5,022)**	699
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	**(5,022)**	699
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of functional currency to presentation currency	**–**	(2,725)
Net other comprehensive loss that will not be reclassified to profit or loss in subsequent periods	**–**	(2,725)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	**(5,022)**	(2,026)
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD	**(70,898)**	112,540
Attributable to:		
Owners of the parent	**(70,922)**	112,540
Non-controlling interests	**24**	–
	(70,898)	112,540

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
30 June 2026

	Notes	**30 June 2026** ***RMB'000*** **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property and equipment		**272,882**	283,673
Prepayments, other receivables and other assets		**191,197**	191,245
Deferred tax assets		**80,925**	81,824
Right-of-use assets		**67,919**	54,929
Goodwill		**399,224**	399,224
Other intangible assets	*7*	**3,087,630**	3,238,760
Equity investment designated at fair value through other comprehensive income		**–**	102,316
Financial asset at fair value through profit or loss		**49,791**	50,000
Total non-current assets		**4,149,568**	4,401,971
CURRENT ASSETS			
Inventories		**437,470**	432,272
Trade receivables	*8*	**143,552**	631,441
Prepayments, other receivables and other assets		**444,726**	79,455
Amounts due from a related party		**2,075**	2,075
Pledged deposits		**331**	393
Cash and cash equivalents		**913,003**	1,054,935
Total current assets		**1,941,157**	2,200,571
CURRENT LIABILITIES			
Trade payables	*9*	**117,037**	322,771
Other payables and accruals		**616,485**	707,700
Refund liabilities		**–**	21,876
Interest-bearing bank and other borrowings		**1,123,240**	1,065,708
Dividends payable		**2,621**	2,695
Tax payables		**57,505**	71,124
Lease liabilities		**19,585**	19,090
Total current liabilities		**1,936,473**	2,210,964
NET CURRENT ASSETS/(LIABILITIES)		**4,684**	(10,393)
TOTAL ASSETS LESS CURRENT LIABILITIES		**4,154,252**	4,391,578

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)
30 June 2026

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
NON-CURRENT LIABILITIES		
Interest-bearing bank borrowings	**–**	374,517
Deferred tax liabilities	**101,167**	100,636
Lease liabilities	**39,609**	27,186
Amounts due to related parties	**314**	588
Other liabilities	**35,846**	37,676
Total non-current liabilities	**176,936**	540,603
Net assets	**3,977,316**	3,850,975
EQUITY		
Equity attributable to owners of the parent		
Share capital	**280**	280
Reserves	**3,979,866**	3,853,549
	3,980,146	3,853,829
Non-controlling interests	**(2,830)**	(2,854)
Total equity	**3,977,316**	3,850,975

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
		(Restated)
Net cash flows from operating activities	**337,364**	295,092
Net cash flows from investing activities	**1,348**	41,753
Net cash flows (used in)/from financing activities	**(459,366)**	331,353
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	**(120,654)**	668,198
Cash and cash equivalents at beginning of period	**1,054,935**	111,703
Effect of foreign exchange rate changes, net	**(21,278)**	(1,439)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	**913,003**	778,462

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

As disclosed in 2025 annual report, on 30 December 2025 (the "**Merger Date**"), the Company completed a very substantial acquisition and reverse takeover with Edding Group Company Limited ("**Edding**"), a company incorporated in the Cayman Islands with limited liability, which involved a new listing application (the "**Merger**"). The Company has applied the reverse acquisition accounting under HKFRS 3. Accordingly, the consolidated financial statements have been prepared as a continuation of the consolidated financial statements of Edding and its subsidiaries ("**Edding Group**"). The results of the Company and its original subsidiaries have been consolidated into the Edding Group's consolidated financial statements since the Merger Date. Comparative information presented in the interim condensed consolidated financial statements has been restated to reflect the financial performance of Edding Group prior to the completion of the Merger.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended HKFRS Accounting Standards for the first time for the current period's financial information.

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Annual Improvements to HKFRS Accounting Standards – Volume 11	Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7

The nature and impact of the amended HKFRS Accounting Standards are described below:

(a) Amendments to HKFRS 9 and HKFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's

accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information. The Group will provide additional disclosures for its equity investments designated at fair value through other comprehensive income in the Group's consolidated financial statements for the year ending 31 December 2026.

(b) Annual Improvements to HKFRS Accounting Standards – Volume 11 set out narrow scope amendments to HKFRS 1, HKFRS 7 (and the accompanying Guidance on implementing HKFRS 7), HKFRS 9, HKFRS 10 and HKAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding HKFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

3. REVENUE

An analysis of the revenue is as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
		(Restated)
Revenue from contracts with customers	**872,732**	1,135,542

4. INCOME TAX

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
		(Restated)
Current	**23,576**	70,201
Deferred	**1,165**	(7,609)
Total tax expense for the period	**24,741**	62,592

5. DIVIDENDS

Special dividends of US$10,000,000 (equivalent to RMB67,405,000) and US$10,000,000 (equivalent to RMB67,737,000) were declared by the Company to the shareholders on a pro-rata basis according to the shares held by them on 5 August 2022 and 6 February 2023, respectively, of which US$6,607,000 (equivalent to RMB46,485,000) was paid during 2025, and US$385,000 (equivalent to RMB2,621,000) remained unpaid as at 30 June 2026.

6. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 1,998,143,726 (2025: 1,667,755,320) outstanding during the period, as adjusted to reflect the rights issue during the period.

The weighted average number of ordinary shares used in the calculation of diluted earnings per share is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued on the deemed vesting of all dilutive potential ordinary shares into ordinary shares.

The calculation of basic and diluted (loss)/earnings per share are based on:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
		(Restated)
(Loss)/earnings		
(Loss)/profit attributable to ordinary equity holders of the parent used in the basic and diluted earnings per share calculation	**(65,836)**	114,566

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
		(Restated)
Shares		
Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation	**1,998,143,726**	1,667,755,320

7. OTHER INTANGIBLE ASSETS

During the six months ended 30 June 2026, an impairment loss of RMB44,812,000 (six months ended 30 June 2025: Nil) had been recognised for an exclusive commercialisation right of Jing Zhu Da.

The intangible asset of Jing Zhu Da was derived from a sub-license agreement with Taizhou EOC Pharma Co., Ltd. (the "**Taizhou EOC**"). Jing Zhu Da was initially licensed to EOC Pharma (Hong Kong) Limited ("**EOC HK**") from Syndax Pharmaceuticals, Inc. ("**Syndax**") and subsequently sublicensed by EOC HK to Taizhou EOC.

Jing Zhu Da is a medicine for treatment of breast cancer, which Taizhou EOC completed the 3 stages of clinical trials, obtained the new drug application approval on 24 April 2024, and started commercial sales since July 2024. The Group obtained exclusive commercialisation right from Taizhou EOC over the life of the medicine.

Syndax terminated its original license agreement with EOC HK. Consequently, EOC HK no longer holds any rights to use and sub-license the relevant patents and intellectual property of Jing Zhu Da, rendering Taizhou EOC unable to fulfil its obligation to grant the Group such commercialisation right. Based on the facts and circumstances as at 30 June 2026, the management believes that the sub-licensing of Jing Zhu Da could not generate future economic benefits, and therefore provided a full impairment provision.

The Company is in active discussions with Taizhou EOC regarding compensation arrangements in respect of the payments made by the Group under the sub-license agreement and any other losses or damages suffered by the Group, and reserves all its rights and remedies against Taizhou EOC and other relevant parties in connection with the foregoing. As at 30 June 2026, the Directors were of the view that the probability of the realisation of the compensation did not reach "virtually certain", and accordingly no contingent asset had been recognized.

Refer to the announcement of the Company dated 5 August 2026 for further details.

8. TRADE RECEIVABLES

An ageing analysis of trade receivables as at the end of each of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**143,552**	559,255
91-180 days	**–**	68,476
181-360 days	**–**	3,710
Total	**143,552**	631,441

9. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 year	**97,700**	260,407
Over 1 year	**19,337**	62,364
Total	**117,037**	322,771

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.eddingpharm.com. The interim report of the Company for the Reporting Period will be published on the aforesaid websites and dispatched to the Shareholders upon request in due course.

By order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 28 August 2026

As at the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.